Title of article :
Study on Anticancer Activity of 4, 4'-[1,4-phenylenebis(1,3,4- thiadiazole-5,2-diyl)] bis(azaneylylidene) bis(methaneylylidene) diphenolon Breast Cancer Cells
Author/Authors :
Saeed, B. M. S Microbiology Department - University of Basrah - Al-Zahraa College of Medicine - Basrah, Iraq , Al-Jadaan, S. A. N Pharmaceutical Chemistry Department - University of Basrah - College of Pharmacy - Basrah, Iraq , Abbas, B. A Department of Microbiology - College of Veterinary Medicine - University of Basrah - Basrah, Iraq
Abstract :
New medicinal compounds are being evaluated due to the increasing prevalence of cancer in human societies
and the necessity to produce new medications for treatment. The new Schiff base compound 4,4'-[1,4-
phenylenebis(1,3,4-thiadiazole-5,2-diyl)] bis (azaneylylidene) bis (methaneylylidene) diphenol, which was
previously produced from the reaction of 5,5' [(1,4-Phenelene) bis (1,3,4-thiadiazol-2-amine)] and the parahydroxy
ben aldehyde was synthesized and different concentrations (250 and 300 mg/mL) of this new
compound were exposed to breast cancer (MCF-7) cells to examine its cytotoxicity effect. Cell line viability,
acridine orange/propidium iodide staining, and DNA fragmentation were assessed in evaluating the antitumor
effect of the new composition. Obtained data from cell viability assays demonstrated cytotoxic activity against
MCF-7 breast cancer cell lines. No fragmentation was observed in DNA fragmentation of the novel compound
base with MCF-7 and Vero cell line. The new Schiff base compound indicated well-defined anti-cancer activity
when treated with breast cancer cells (MCF-7). The compound blocked the proliferation of cancer cells without
apoptosis. As a consequence of the findings, it was recommended to use this compound in treating breast
cancer.
Keywords :
Thiadiazole Compound , DNA Laddering Assay , Breast Cancer
Journal title :
Archives of Razi Institute